– USA, CO – Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis (CF), today announced that Paul Sekhri, president and chief executive officer of Lycera Corp., has joined the Company’s Board of Directors, effective February 25, 2016. The Company also announced that Jonathan Leff, who has served as a director since April 2014, has elected to step down from the Board of Directors when his term expires at the Company’s annual stockholders meeting in April 2016.
“We are pleased to welcome Mr. Sekhri to the board during this important period of growth for the Company. His biopharmaceutical leadership experience will be of significant value for the group as we advance our clinical program and commercial efforts for N91115,” said Jon Congleton, president and chief executive officer. “On behalf of the board, we also want to thank Mr. Leff for his contributions to Nivalis over the years and wish him the best in all of his future endeavors.”
Mr. Sekhri has nearly 30 years of commercial development experience, with a focus on creating and building therapeutic and disease area strategy for biopharmaceutical companies. He currently serves as Lycera’s president and chief executive officer. Prior, he served as senior vice president, integrated care for Sanofi and as group executive vice president, global business development and chief strategy officer for Teva Pharmaceutical Industries, Ltd. Prior to joining Teva, he held senior leadership roles at TPG Biotech, the life sciences venture capital arm of TPG Capital, Cerimon Pharmaceuticals, ARIAD Pharmaceuticals, Inc., and Novartis Pharma AG.
“I am delighted to join the Nivalis team and look forward to contributing my early commercial development experience as the Company advances its clinical program and regulatory strategy for the first CF therapy believed to stabilize the cystic fibrosis transmembrane conductance regulator, or CFTR protein,” said Paul Sekhri.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.